AUTHOR INDEX

(P = Proceedings)

AARONS L. *see* HERRICK A.L.
ABDELMAWLA A.H., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Bisoprolol attenuates noradrenaline- and phenylephrine-evoked vasoconstriction in man, 443P
ABDELMAWLA A.H., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Effects of different congestion pressures on the diameter of the dorsal hand vein and its apparent sensitivity to noradrenaline, 449P
ABDI Y.A. *see* SCHMIDER J.
ABERG G. *see* EATON E.A.
ABUSAAD I. *see* SODHI M.S.
AGACHE P. *see* BENDRISS E.K.
AHMAD A. *see* HE G-W.
AITCHISON K.J. *see* SODHI M.S.
ALDERSHVILE J. *see* KELBAEK H.
ALIYAR C.A. *see* DRAKE J.
ALLAIN H. *see* PATAT A.
ALLOTT R.L., PIRMOHAMED M., KITTERINGHAM N.R. & PARK B.K. Glutathione S-transferase T1 polymorphism and susceptibility to carbamazepine hypersensitivity, 463P
ALVAREZ F.J. *see* DEL RIO M.C.
ANDERER P. *see* SALETU B.
ANGELO H.R. *see* HERRSTEDT J.
ARRANZ M.J. *see* SODHI M.S.
ARTHUR N. *see* McGETTIGAN P.
ASHTON C.H. *see* MOORE V.R.
ASHTON C.H. *see* WEBB E.
ASHTON M. *see* HASSAN ALIN M.
ASSIN M. *see* TRELOAR A.J.
AU G.H.K. *see* CHUA D.T.T.

BAAN J., CHANG P.C., VERMEIJ P., PFAFFENDORF M. & VAN ZWEITEN P.A. Effects of intra-arterial and oral losartan on flow responses to angiotensin II in the human forearm, 449P
BABER N. *see* CHAN R.
BACK D.J. *see* HOGGARD P.G.
BACK D.J. *see* TOMLINSON E.S.
BACK D.J. *see* VEAL G.J.
BADER A. *see* CHRISTIANS U.
BADIA P. *see* COMBIS J-M.
BAGHERI H. *see* LEMOZIT J.P.
BALL D.M. *see* SODHI M.S.
BALL S.E. *see* OTTON S.V.
BARANGE K. *see* COMBIS J-M.
BARBHAIYA R.H. *see* MARATHE P.H.
BARBHAIYA R.H. *see* SHYU W.C.
BARBHAIYA R.H. *see* SRINIVAS N.R.
BARENNES H., PUSSARD E., MAHAMAN SANI A., CLAVIER F., KAHIATANI F., GRANIC G., HENZEL D., RAVINET L. & VERDIER R. Efficacy and pharmacokinetics of a new intrarectal quinine formulation in children with *Plasmodium falciparum* malaria, 389
BARKER D.P. *see* BARRETT D.A.
BARRADAS M.A. *see* JAGROOP I.A.
BARRETT D.A., BARKER D.P., RUTTER N., PAWULA M. & SHAW P.N. Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions, 531
BARRY M.G. *see* HOGGARD P.G.
BARRY M.G. *see* VEAL G.J.
BARTO R. *see* SIPS A.J.A.M.
BARTOLI A. *see* GIACCONE M.
BATTEIGER B. *see* SRINIVAS N.R.
BAYOD F. *see* SOBHANI I.
BECHTEL P.R. *see* BENDRISS E.K.
BECHTEL Y. *see* BENDRISS E.K.
BENDRISS A. *see* BENDRISS E.K.
BENDRISS E.K., BECHTEL Y., BENDRISS A., HUMBERT P.H., PAINTAUD G., MAGNETTE J., AGACHE P. & BECHTEL P.R. Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis, 421
BENITZ J. *see* CARRILLOP J.A.
BENJAMIN P.E. *see* ROLAN P.E.
BENNETT P.N. *see* NOTARIANI L.J.
BERGENDAL L. *see* GRAHAM S.
BIDAULT R. *see* VAUZELLE-KERVROEDAN F.
BINKLEY S.N. *see* RING B.J.
BIRKETT D.J. *see* GRAHAM S.
BISCHOFF A. *see* MICHEL M.C.
BITSIOS P., LANGLEY R.W., SZABADI E. & BRADSHAW C.M. Comparison of the effects of clonidine on tyramine- and methoxamine-evoked mydriasis in man, 269
BJORKMAN A. *see* HASSAN ALIN M.
BLECK J.S., THIESEMANN C., KLIEM V., CHRISTIANS U., HECKER H., REPP H., FREI U., WESTHOFF-BLECK M., MANNS M. & SEWING K.F. Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite pattern, 551
BOCHNER F. *see* SOMOGYI A.A.
BODDY A.V. *see* YULE S.M.
BONNARBY P., DESMEULES J., RUDAZ S., LEEMANN T., VEUTHEY J-L. & DAYER P. Stereoselective interaction between piroxicam and acenocoumarol, 525
BOON N.A. *see* NEWBY D.E.
BOON N.A. *see* NEWBY D.E.
BOULTON D.W. & FAWCETT J.P. Enantioselective disposition of salbutamol in man following oral and intravenous administration, 35
BOWES S.G. *see* KIROLLOS C.
BRADSHAW C.M. *see* ABDELMAWLA A.H.
BRADSHAW C.M. *see* ABDELMAWLA A.H.
BRADSHAW C.M. *see* BITSIOS P.
BRADSHAW C.M. *see* MORTLOCK S-A.
BRAGER N.P.D., CAMPBELL N.R.C., REISCH H., CHAUDHURI M. & RABIN H.R. Reduced renal fractional excretion of lithium in cystic fibrosis, 157
BREIMER D.D. *see* STEVENINCK A.L.
BROOKMAN L. *see* ROLAN P.E.
BROWN M.J. *see* JIA H.
BULLING M. *see* ROBERTS J.
BULLINGHAM R., GOLDBLUM R. & SCHIFF M. Effects of food and antacid on the pharmacokinetics of single doses of mycophemolate mofetil in rheumatoid arthritis patients, 513
BURNS N., FLAPAN A.D., WRIGHT R.A., FRANCIS M.A. & WILLIAMS B.C. Acute captopril administration increases the heart rate response to atropine in patients with chronic cardiac failure, 452P
BUSATTO G.F. *see* PILOWSLY L.S.
BUSCH U. *see* NARJES N.
BYE A. *see* FALCOZ C.
BYE A. *see* MACKIE A.E.
BYE A., LACEY L.F., GUPTA S. & POWELL J.R. Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg^{-1}) 129

CALVERT A. *see* KAMALI F.
CAMPBELL N.R.C. *see* BRAGER N.P.D.
CAPONE P. *see* SUTTON J.A.
CAPPUGI P. *see* DEL BIANCO E.
CARRILLOP J.A. & BENITZ J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine, 605
CASEY E.B. *see* HALL M.
CASTENADA-HERNANDEZ G., PALMA-AGUIRRE J.A., MONTOYA-CABRERA M.A. & FLORES-MURRIETA F.J. Letter to the Editors. Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects, 433
CESKOVA E. *see* HADASOVA E.
CHAN R. *see* McGETTIGAN P., CHAN R., SHEEHAN R., WESTGATE C., SMITH J. & BABER N. A study to investigate the effects of angiotensin II on peak systolic pulmonary artery pressures using transthoracic Doppler echocardiography in healthy volunteers, 447P
CHANG P.C. *see* BAAN J.
CHARLES B.G. *see* LEE T.C.

© 1996 Blackwell Science Ltd

CHARLETT A. *see* KIROLLOS C.
CHARLETT A. *see* PURKISS A.G.
CHARRANSOL A. *see* DEMOLIS J-L.
CHAUDHURI M. *see* BRAGER N.P.D.
CHENG A.C.K. *see* CHUA D.T.T.
CHEUNG S.W. *see* OTTON S.V.
CHIANG S-C. *see* SETO W-H.
CHING D. *see* PURKISS A.G.
CHING T-Y. *see* SETO W-H.
CHOY D. *see* CHUA D.T.T.
CHRISTIANS U. *see* BLECK J.S.
CHRISTIANS U., SCHMIDT D., BADER A., LAMPEN A., SCHOTTMANN R., LINCK A. & SEWING K-F. Identification of drugs inhibiting the *in vitro* metabolism of tacrolimus by human liver microsomes, 187
CHUA D.T.T., SHAM J.S.T., AU G.H.K., CHOY D., KWONG D.L.W., YAU C.C. & CHENG A.C.K. The anti-emetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy, 403
CHURCHUS R. *see* SEABER E.
CIEUTA C. *see* VAUZELLE-KERVROEDAN F.
CLARK D.J. & LIPWORTH B.J. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol, 247
CLARK D.J., GORDON-SMITH J., McPHATE G., CLARK G.A. & LIPWORTH B.J. Lung bioavailability of generic and innovator salbutamol metered-dose inhalers, 459P
CLARK D.J., TAN K.S., CLARK G.A. & LIPWORTH B.J. Evaluation of plasma and urine pharmacokinetics of nebulized salbutamol in COPD, 440P
CLARK G.A. *see* CLARK D.J.
CLAVIER F. *see* BARENNES H.
CLEOPHAS T.J.M. Crossover trials are only useful when there is a positive correlation between the response to different treatment modalities, 235
COHEN A.F. *see* STEVENINCK A.L.
COLE M. *see* YULE S.M.
COLEMAN T., ELLIS S.W., MARTIN I.J., LENNARD M.S. & TUCKER G.T. MPTP is *N*-demethylated by CYPs 2D6, 1A2 and 3A4: implications for susceptibility to Parkinson's disease, 438P
COLLART L. *see* DESMEULES
COLLIER D.A. *see* SODHI M.S.
COLLINS J. & JOHNSTON A. Motivation of volunteers to participate in clinical research, 467P
COMBIS F. *see* COMBIS J-M.
COMBIS J-M., VINEL J-P., BADIA P., BARANGE K., PAYEN J-L., COMBIS F., DESMORAT H. & PASCAL J-P. Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis, 409
COSTA D.C. *see* PILOWSLY L.S.
COUTIE W.J. *see* TAN K.S.
CRAWFORD F.E. *see* DRAKE J.
CRONJE H.S. *see* MULLER F.O.
CUTLER D. *see* TETT S.

D'ATHIS P. *see* VAUZELLE-KERVROEDAN F.
DAHL L-L. *see* SCHMIDER J.
DALY A.K. *see* FORD G.A.
DAUL A.E. *see* SCHAFERS R.F.
DAY R. *see* TETT S.
DAY R.O. *see* GRAHAM S.
DAY R.O. *see* WALKER J.S.
DAYER P. *see* BONNARBY P.
DAYER P. *see* DESMEULES
DE BRUIJN E.A. *see* SOEDIRMAN J.R.
DEL BIANCO E., GEPPETTI P., ZIPPI P., ISOLANI D., MAGINI B. & CAPPUGI P. The effects of repeated dermal application of capsaicin to the human skin on pain and vasodilatation induced by intradermal injection of acid and hypertonic solutions, 1
DEL RE G. *see* SUTTON J.A.
DEL RIO M.C., PRADA C. & ALVAREZ F.J. The use of medication and alcohol among the Spanish population, 253
DEMOLIS J-L., CHARRANSOL A., FUNCK-BRENTANO C. & JAILLON P. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers, 499P
DESMEULES J. *see* BONNARBY P., DESMEULES J., PIGUET V., COLLART L. & DAYER P. Contribution of monoaminergic modulation to the analgesic effect of tramadol, 7
DESMORAT H. *see* COMBIS J.-M.
DOBBS R.J. *see* KIROLLOS C.
DOBBS R.J. *see* PURKISS A.G.
DOBBS S.M. *see* KIROLLOS C.
DOBBS S.M. *see* PURKISS A.G.
DOBROCKY P. *see* NOTARIANI L.J.
DOMBERNOWSKY P. *see* HERRSTEDT J.
DOONA M., McGETTIGAN P., GOLDEN J., O'CONNELL T. & FEELY J. Generic prescribing in hospitals: concerns of the prescriber and knowledge of drug prices, 469P
DOUMA C.E. *see* VEERMAN D.P.
DRAKE J., KIRKPATRICK C.T., ALIYAR C.A., CRAWFORD F.E., GIBSON P. & NORTH C.E. Effect of food on the comparative pharmacokinetics of modified release morphine tablet formulations: Oramorph ST and MST Continus, 417
DUCHARME J., DUCHARME M.P. & WAINER I.W. Enantioselective disposition of hydroxychloroquine, 347
DUCHARME M.P. *see* DUCHARME J.
DULAC O. *see* VAUZELLE-KERVROEDAN F.
DURSUN S.M. *see* PATEL J.K.M.
DUSCI L.J. *see* WOJNAR-HORTON R.E.

EADINGTON D.W. *see* HAYNES W.G.
EAGLES C.J., KENDALL M.J. & MAXWELL S. A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic studies, 381
EATON E.A., WALLE U.K., WILSON H.M., ABERG G. & WALLE T. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells, 201
EBERT U., SIEPMANN M., WESNES K. & KIRCH W. Correlation between the pharmacokinetics and electroencephalographic and psychological performance parameters under administration of scopolamine, 453P
ELL P.J. *see* PILOWSLY L.S.
ELLIS S.W. *see* COLEMAN T.

FAGAN T.C. *see* WALLE T.
FALCOZ C., MACKIE A.E., McDOWALL J., McRAE J., YOGENDRAN L., VENTRESCA G.P. & BYE A. Oral bioavailability of fluticasone propionate in healthy subjects, 459P
FAWCETT J.P. *see* BOULTON D.W.
FEELY J. *see* DOONA M.
FEELY J. *see* HALL M.
FEELY J. *see* McGETTIGAN P.
FEELY J. *see* SHARMA S.C.
FEELY J. *see* WEN Y.
FERRO C.J. *see* NEWBY D.E.
FERRO C.J., HAYNES W.G. & WEBB D.J. Role of neutral endopeptidase in control of peripheral vascular tone in man, 440P
FLAPAN A.D. *see* BURNS N.
FLEISCHER W.K. *see* THURAUF N.
FLENADY V.G. *see* LEE T.C.
FLETCHER E. *see* THOMAS M.
FLORES-MURRIETA F.J. *see* CASTENADA-HERNANDEZ G.
FLOTEN S. *see* HE G-W.
FORD G.A. *see* HUSSAIN R.M.
FORD G.A., IDLE J.R., McBLANE J.W., PRICE J.S., WOOD S.M. & DALY A.K. Use of the yellow card system to identify and genotype patients with terodiline cardiotoxicity, 462P
FOURNEY A. *see* LEENEN F.H.H.
FRANCIS M.A. *see* BURNS N.
FRANKE G. *see* HADASOVA E.
FRASER I.J. *see* HUSSEIN Z.
FREI U. *see* BLECK J.S.
FULLER R.W. *see* MACKIE A.E.
FUNCK-BRENTANO C. *see* DEMOLIS J-L.
FURNARY A. *see* HE G-W.

GAIST D., HALLAS J., HANSEN N-C.G. & GRAM L.F. Are young adults with asthma treated sufficiently with inhaled steroids? A population based study on prescription data from 1991 and 1994 285
GANDON J.M. *see* PATAT A.
GATELY H. *see* HE G-W.
GATHUA S. *see* WATKINS W.M.
GATTI G. *see* GIACCONE M.

GEORGE E. *see* ROSTAMI-HODJEGAN A.
GEPPETTI P. *see* DEL BIANCO E.
GERTZ B.G. *see* NEWBY D.E.
GHEBRESELASIE K. *see* KINIRONS M.T.
GIACCONE M., BARTOLI A., GATTI G., MARCHISELLI R., PISANI F., LATELLA M.A. & PERUCCA E. Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients, 575
GIBSON P. *see* DRAKE J.
GIESCHKE R. *see* STEVENINCK A.L.
GIFFORD L.A. *see* HERRICK A.L.
GILKS C.F. *see* WATKINS W.M.
GODLEWSKI G. *see* NOTARIANI L.J.
GOLDBLUM R. *see* BULLINGHAM R.
GOLDEN J. *see* DOONA M.
GOLDEN J. *see* McGETTIGAN P.
GORDON-SMITH J. *see* CLARK D.J.
GRAHAM S., DAY R.O., WONG H., McLACHLAN A.J., BERGENDAL L., MINERS J.O. & BIRKETT D.J. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects, 299
GRAM L.F. *see* GAIST D.
GRANIC G. *see* BARENNES H.
GRANT T.C. *see* LEE T.C.
GREENBLATT D.J. *see* SCHMIDER J.
GREENE D.S. *see* MARATHE P.H.
GRENMAN D.M. *see* HERRICK A.L.
GRIFFEN K. *see* HERRICK A.L.
GROENEWOUD G. *see* MULLER F.O.
GRONNEROD O. *see* GULLESTAD L.
GROSS A.S., PHILLIPS A.C., RIEUTORD A. & SHENFIELD G.M. The influence of the sparteine/debrisoquine genetic polymorphism on the dispostion of dexfenfluramine, 311
GRUNBERGER J. *see* SALETU B.
GRUTER J. *see* SOEDIRMAN J.R.
GULLESTAD L., HALLEN J., MEDBO J.I., GRONNEROD O., HOLME I. & SEJERSTED O.M. The effect of acute *vs* chronic treatment with β-adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women, 57
GUPTA S. *see* BYE A.
GUSTAFSSON L.L. *see* SCHMIDER J.

HACKETT L.P. *see* WOJNAR-HORTON R.E.
HADASOVA E., FRANKE G., ZSCHIESCHE M., CESKOVA E., ZELENKOVA O. & SIEGMUND W. Debrisoquine 4-hydroxylation and sulphamethazine *N*-acetylation in patients with schizophrenia and major depression, 428
HALL M., McCORMACK P. & FEELY J. Are hospital pharmacists better than doctors or nurses at identifying commonly prescribed drugs?, 469P
HALL M., McCORMACK P., HEMERYCK L., CASEY E.B. & FEELY J. Patient-generated adverse drug-reaction (ADR) reports, 468P
HALLAS J. *see* GAIST D.
HALLEN J. *see* GULLESTAD L.
HANCK A. *see* SOEDIRMAN J.R.
HAND M.F. *see* HAYNES W.G.
HAND M.F. *see* NEWBY D.E.
HANSEN N-C.G. *see* GAIST D.
HANZE J. *see* MICHEL M.C.
HARMATZ J.S. *see* SCHMIDER J.
HARTIGAN-GO K. & THOMAS S.H.L. Reproducibility of repeated manual measurements of QT interval and QT dispersion in healthy subjects, 448P
HARTIGAN-GO K. *see* HUSSAIN R.M.
HARTIGAN-GO K. *see* THOMAS S.H.L.
HASLER J.A. *see* SCHMIDER J.
HASSAN ALIN M., ASHTON M., KIHAMIA C.M., MTEY G.J.B. & BJORKMAN A. Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria, 587
HAWKESFORD J.E. *see* SEYMOUR R.A.
HAYES J.R. *see* NUGENT A.G.
HAYNES W.G. *see* FERRO C.J.
HAYNES W.G., HAND M.F., EADINGTON D.W., LEE M.R. & WEBB D.J. Nitric oxide regulates renal haemodynamic and tubular function in man, 441P
HE G-W., YANG C-Q., GATELY H., FURNARY A., SWANSON J., AHMAD A., FLOTEN S., WOOD J. & STARR A. Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries, 101
HECKER H. *see* BLECK J.S.
HEINEMANN L. *see* SPITZER W.O.
HEINZEL G. *see* NARJES N.
HELLER S.R. *see* ROSTAMI-HODJEGAN A.
HEMERYCK L. *see* HALL M.
HENZEL D. *see* BARENNES H.
HERRICK A.L., GRENMAN D.M., GRIFFEN K., AARONS L. & GIFFORD L.A. Lack of interaction between flucloxacllin and methotrexate in patients with rheumatoid arthritis, 223
HERRSTEDT J., JORGENSEN M., ANGELO H.R., ROMER RASSING M., MOLLER-SONNERGAARD J. & DOMBERNOWSKY P. Bioavailability of the antiemetic metopimazine given as a microenema, 613
HERXHEIMER A. Book review. Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation by John Abraham, 351
HILDEBRANDT P. *see* KELBAEK H.
HOBBIGER S.F. *see* HUSSEIN Z.
HOGGARD P.G., VEAL G.J., BARRY M.G., KHOO S. & BACK D.J. Intracellular phosphorylation interactions between nucleoside analogues, 474P
HOHLFELD T. *see* KLOCKENBUSCH W.
HOLME I. *see* GULLESTAD L.
HOUSOM L. *see* WILLIAMS P.M.
HUAI H.B. *see* KINIRONS M.T.
HUANG M.L. *see* KAMALI F.
HUBNER G.H. *see* WEISS M.
HUBNER I.G. *see* WEISS M.
HUMBERT P.H. *see* BENDRISS E.K.
HUNDT H.K.L. *see* MULLER F.O.
HUNT W.B. *see* KIROLLOS C.
HUSSAIN R.M., HARTIGAN-GO K., THOMAS S.H.L. & FORD G.A. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence, 73
HUSSEIN Z., FRASER I.J., LEES K.R., MUIR K.W., LUNNON M.W., HOBBIGER S.F. & POSNER J. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions, 505

IDLE J.R. *see* FORD G.A.
IDLE J.R. *see* YULE S.M.
ILETT K.F. *see* WOJNAR-HORTON R.E.
INABA T. *see* OTTON S.V.
INMAN W.H.W., LEWIS S.C., PAYNE S., RAWLINS M.D. & WOOD S.M. Letter to the Editors. Attitudes to adverse drug reaction reporting, 435
ISOLANI D. *see* DEL BIANCO E.

JACKSON S.H.D. Meeting report. Paul Turner Memorial Symposium, 353
JACOBS M-C. *see* VEERMAN D.P.
JAGROOP I.A., BARRADAS M.A. & MIKHAILIDIS D.P. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation, 163
JAILLON P. *see* DEMOLIS J-L.
JENNINGS M., SWEETLAND H., SMITH C.A.D., WOLF C.R., LENNARD M.S., TUCKER G.T., WOODS H.E. & ROGERS K. Lack of relationship between the debrisoquine (CYP2D6) and mephenytoin (CYP2C19) oxidation polymorphisms and susceptibility to breast cancer, 461P
JIA H., TRUTWEIN D. & BROWN M.J. Levels of GTPgammaS-stimulated adenylyl cyclase activity in human lymphocytes: effects of GSα genotype, 465P
JOHNSTON A. *see* COLLINS J.
JOHNSTON G.D. *see* MAGUIRE S.M.
JOHNSTON G.D. *see* McGURK C.
JOHNSTON G.D. *see* NUGENT A.G.
JONES R.W. *see* NOTARIANI L.J.
JONES T. *see* RILEY R.J.
JORGENSEN M. *see* HERRSTEDT J.

KAHIATANI F. *see* BARENNES H.
KAMALI F. & HUANG M.L. Increased systemic availability of loperamide after oral administration of loperamide and loperamide oxide with cotrimoxazole, 129

KAMALI F. *see* WEBB E.
KAMALI F., TOMMEY R., WALLACE R.J., CALVERT A., SOONS P.A. & WOODING S.J. The safety of sumatriptan administration 2 h after subcutaneous injection of alniditan, a new anti-migraine drug, in healthy volunteers, 456P
KELBAEK H., ALDERSHVILE J., SKAGEN K., HILDEBRANDT P. & NIELSEN S.L. Pre- and afterload reduction in chronic mitral regurgitation: a double-blind randomized placebo-controlled trial of the acute and 2 weeks' effect of nifedipine or isosorbide dinitrate therapy, 493
KELLY P. *see* WEBB E.
KELLY P.J. *see* SEYMOUR R.A.
KENDALL M.J. *see* EAGLES C.J.
KERWIN R.W. Abstract. New antipsychotics: stimulating the renaissance of the pharmacology of schizophrenia, 356
KERWIN R.W. *see* PILOWSLY L.S.
KERWIN R.W. *see* SODHI M.S.
KHOO S. *see* HOGGARD P.G.
KHOO S. *see* VEAL G.J.
KHOO Y.M. *see* LEE H.S.
KIHAMIA C.M. *see* HASSAN ALIN M.
KILMINSTER S.G. *see* SUTTON J.A.
KIM R.B. *see* O'SHEA D.
KINIRONS M.T., LANG C.C., HUAI H.B., GHEBRESELASIE K., SHAY S., ROBIN D.W. & WOOD A.J.J. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity, 69
KIRCH W. *see* EBERT U.
KIRKPATRICK C.T. *see* DRAKE J.
KIROLLOS C., CHARLETT A., O'NEILL C.J.A., KOSIK R., MOZOL K., PURKISS A.G., BOWES S.G., NICHOLSON P.W., HUNT W.B., WELLER C., DOBBS S.M. & DOBBS R.J. Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in Parkinsonism, 557
KITCHENER S., MALEKOTTOODJARY N. & McCLELLAND G.R. Adverse effects from placebo-treated healthy volunteers, 473P
KITTERINGHAM N.R. *see* ALLOTT R.L.
KITTERINGHAM N.R. *see* MADDEN S.
KITTERINGHAM N.R. *see* PARK B.K.
KLIEM V. *see* BLECK J.S.
KLOCKENBUSCH W., HOHLFELD T., WILHELM M., SOMVILLE T. & SCHROR K. Platelet PGI 2 receptor affinity is reduced in pre-eclampsia, 616
KNUPP C.A. *see* SRINIVAS N.R.
KOBAL G. *see* THURAUF N.
KONIG P. *see* SALETU B.
KOSIK R. *see* KIROLLOS C.
KOU M. *see* SETO W-H.
KRISHNA S., SUPANARANOND W., PUKRITTAYAKAMEE S., KUILE F.T., RUPRAH M. & WHITE N.J. The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria, 29
KUILE F.T. *see* KRISHNA S.
KUMANA C.R. *see* SETO W-H.
KWONG D.L.W. *see* CHUA D.T.T.

LACEY L.F. *see* BYE A.
LADER M. Abstract. Recent developments in the treatment of anxiety and depression, 356
LAMPEN A. *see* CHRISTIANS U.
LANG C.C. *see* KINIRONS M.T.
LANGLEY R.W. *see* ABDELMAWLA A.H.
LANGLEY R.W. *see* BITSIOS P.
LANGLEY R.W. *see* MORTLOCK S-A.
LAPEYRE-MESTRE M. *see* LEMOZIT J.P.
LATELLA M.A. *see* GIACCONE M.
LAUDER I.J. *see* SETO W-H.
LEE H.S., TI T.Y., LYE W.C., KHOO Y.M. & TAN C.C. Paracetamol and its metabolites in saliva and plasma in chronic dialysis patients, 41
LEE J.S. *see* MARATHE P.H.
LEE M.R. *see* HAYNES W.G.
LEE T.C., CHARLES B.G., STEER P.A., FLENADY V.G. & GRANT T.C. Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea, 191
LEEMANN T. *see* BONNARBY P., LEENEN F.H.H., FOURNEY A., NOTMAN G. & TANNER J. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) *vs* short (diltiazem) elimination half-life, 83
LEES K.R. *see* HUSSEIN Z.
LEMOZIT J.P., PETIT DE LA RHODIERE G., LAPEYRE-MESTRE M., BAGHERI H. & MONTASTRUC J.L. A comparative study of adverse drug reactions reported through hospital and private medicine, 166
LENNARD M.S. *see* COLEMAN T.
LENNARD M.S. *see* JENNINGS M.
LEWIS M. *see* SPITZER W.O.
LEWIS S.C. *see* INMAN W.H.W.
LI R.C. *see* RAYMOND K.
LIEFHOLD J. *see* THURAUF N.
LINCK A. *see* CHRISTIANS U.
LINGFORD-HUGHES A. Book review. Benzodiazepine Receptor Inverse Agonists edited by M. Sarter, 259
LINZMAYER L. *see* SALETU B.
LIP G.Y.H. & LOWE G.D.O. Warfarin and aspirin as thromboprophylaxis in atrial fibrillation, 369
LIPWORTH B.J. *see* CLARK D.J.
LIPWORTH B.J. *see* TAN K.S.
LOGAN C.J. *see* RILEY R.J.
LOVE M.P. *see* NEWBY D.E.
LOWE G.D.O. *see* LIP G.Y.H.
LUNNON M.W. *see* HUSSEIN Z.
LYE W.C. *see* LEE H.S.
MACDONALD A.J.D. *see* TRELOAR A.J.
MACKIE A.E. *see* FALCOZ C.
MACKIE A.E., VENTRESCA G.P., FULLER R.W. & BYE A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects, 539
MACKLIN B.S. *see* ROBERTS J.
MACONOCHIE J.G. *see* THOMAS M.
MADDEN S., MAGGS J.L., KITTERINGHAM N.R., PIRMOHAMED M. & PARK B.K. Bioactivation of carbamazepine in the rat *in vivo*, 464P
MAES R.A.A. *see* SOEDIRMAN J.R.
MAGGS J.L. *see* MADDEN S.
MAGGS J.L. *see* TOMLINSON E.S.
MAGINI B. *see* DEL BIANCO E.
MAGNETTE J. *see* BENDRISS E.K.
MAGUIRE S. *see* NUGENT A.G.
MAGUIRE S.M., NUGENT A.G., McGURK C., JOHNSTON G.D. & NICHOLLS D.P. Abnormal vasular responses in congestive heart failure, 452P
MAHAMAN SANI A. *see* BARENNES H.
MALEKOTTOODJARY N. *see* KITCHENER S.
MANN R.D. *see* WILTON L.V.
MANNS M. *see* BLECK J.S.
MARATHE P.H., LEE J.S., GREENE D.S. & BARBHAIYA R.H. Comparison of the steady-state pharmacokinetics of nefadozone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening, 21
MARCHISELLI R. *see* GIACCONE M.
MARSDEN C.A. Abstract. Antidepressants: backwards into the future, 355
MARTIN C.A. *see* RILEY R.J.
MARTIN I.J. *see* COLEMAN T.
MASIMAMASIMIREMBWA C.M. *see* SCHMIDER J.
MASOOD A.R. & THOMAS S.H.L. Systemic absorption of inhaled neublised morphine, 465P
MASOOD A.R. & THOMAS S.H.L. Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects, 250
MATTILA M.J., SEPPALA T., ZIELENIUK I., PATAT A. & ROSENZWEIG P. Oral single doses of amisulpride do not interact with ethanol on performance and memory, 454P
MAXWELL S. *see* EAGLES C.J.
MBERU E.K. *see* WATKINS W.M.
McAULEY D.F. *see* McGURK C.
McBLANE J.W. *see* FORD G.A.
McCLELLAND G.R. *see* KITCHENER S.
McCORMACK P. *see* HALL M.
McDOWALL J. *see* FALCOZ C.
McFARLANE L.C. *see* TAN K.S.
McGETTIGAN P. & FEELY J. Limited impact on reinstatement of medicines to a national limited list, 470P

McGETTIGAN P. *see* DOONA M.
McGETTIGAN P., GOLDEN J., ARTHUR N. & FEELY J. Adverse drug reaction reporting by hospital doctors: knowledge, use of the system and response to intervention, 471P
McGETTIGAN P., GOLDEN J., CHAN R. & FEELY J. Sources of information used by hospital doctors when prescribing new drugs, 471P
McGURK C. *see* MAGUIRE S.M.
McGURK C. *see* NUGENT A.G.
McGURK C., NUGENT A.G., McAULEY D.F. & JOHNSTON G.D. Direct effects of frusemide in the human dorsal hand vein, 450P
McLACHLAN A.J. & TETT S.E. Letter to the Editors. Enantioselective disposition of hydrochloroquine, 347
McLACHLAN A.J. & TETT S.E. Pharmacokinetics of fluconazole in people with HIV infection: a population analysis, 291
McLACHLAN A.J. *see* GRAHAM S.
McLEOD H.L. *see* McMURROUGH J.
McMILLAN A-M. *see* PATEL J.K.M.
McMURROUGH J. & McLEOD H.L. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population, 425
McPHATE G. *see* CLARK D.J.
McRAE J. *see* FALCOZ C.
MEDBO J.I. *see* GULLESTAD L.
MENDEL C.M. *see* NEWBY D.E.
MICHEL M.C. *see* SCHAFERS R.F.
MICHEL M.C., HANZE J., BISCHOFF A. & PASCHER W. Are alleles of the human Y1 neuropeptide Y receptor gene associated with alterations of cardiovascular or metabolic parameters?, 476P
MIGNON M. *see* SOBHANI I.
MIKHAILIDIS D.P. *see* JAGROOP I.A.
MINERS J.O. *see* GRAHAM S.
MOHLER H. Abstract.Biochemical pharmacology of anti-anxiety drugs, 355
MOLLER-SONNERGAARD J. *see* HERRSTEDT J.
MONTASTRUC J.L. *see* LEMOZIT J.P.
MONTOYA-CABRERA M.A. *see* CASTENADA-HERNANDEZ G.
MOORE V.R., ASHTON C.H. & SEYMOUR R.A. Experimental pain techniques, 349
MORGENTHEIN E.A. *see* SHYU W.C.
MORTLOCK S-A., LANGLEY R.W., BRADSHAW C.M. & SZABADI E. Effect of locally-applied prazosin on the pupillary light reflex, 451P
MOULD G.P. *see* SUTTON J.A.
MOZOL K. *see* KIROLLOS C.
MTEY G.J.B. *see* HASSAN ALIN M.
MUHIA D.K. *see* WATKINS W.M.
MUIR K.W. *see* HUSSEIN Z.
MULLER F.O., SCHALL R., HUNDT H.K.L., GROENEWOUD G., UNGERER M.J., CRONJE H.S. & SCHUMANN F. Letter to the Editors. Pharmacokinetics of aprotinin in two patients with chronic renal impairment, 619
MULLINS F. *see* ROLAN P.E.
MUNCK A.C. *see* SCHAFERS R.F.
MUNGAI M. *see* WATKINS W.M.
MURRAY M. *see* NADIN L.

NADIN L. & MURRAY M. All-*trans*-retinoic acid 4-hydroxylation in human liver microsomes: *in vitro* modulation by therapeutic retinoids, 609
NARJES N., TURCK D., BUSCH U., HEINZEL G. & NEHMIZ G. Pharmacokinetics and tolerability of meloxicam after i.m. administration, 135
NEHMIZ G. *see* NARJES N.
NETELENBOS J.C. *see* SIPS A.J.A.M.
NEUVONEN P.J. *see* VARHE A.
NEWBY D.E., HAND M.F., FERRO C.J., LOVE M.P., BOON N.A. & WEBB D.J. Forearm vasodilatation to substance P is more dependent on nitric oxide than vasodilatation to acetylcholine, 444P
NEWBY D.E., SCIBERRAS D.G., MENDEL C.M., GERTZ B.G., BOON N.A. & WEBB D.J. Intra-arterial substance P-mediated forearm vasodilatation: human pharmacology and tolerability, 445P
NICHOLLS D.P. *see* MAGUIRE S.M.
NICHOLSON P.W. *see* KIROLLOS C.
NIELSEN S.L. *see* KELBAEK H.
NOHRIA V. *see* PILOWSLY L.S.
NORTH C.E. *see* DRAKE J.
NOTARIANI L.J., DOBROCKY P., GODLEWSKI G., JONES R.W. & BENNETT P.N. Caffeine as a metabolic probe, 169
NOTMAN G. *see* LEENEN F.H.H.
NUGENT A.G. *see* MAGUIRE S.M.
NUGENT A.G. *see* McGURK C.
NUGENT A.G., McGURK C. & JOHNSTON G.D. Forearm vascular responses to serotonin are not mediated by products of cyclooxygenase, 241
NUGENT A.G., McGURK C., HAYES J.R. & JOHNSTON G.D. Vascular response to glyceryl trinitrate and sodium nitroprusside in type 2 diabetes mellitus, 443P
NUGENT A.G., McGURK C., MAGUIRE S., HAYES J.R. & JOHNSTON G.D. Effects of cyclooxygenase inhibition on endothelium-dependent vasodilatation in type 2 diabetes mellitus, 450P
NUNN P. *see* WATKINS W.M.

O'CONNELL T. *see* DOONA M.
O'NEILL C.J.A. *see* KIROLLOS C.
O'NEILL C.J.A. *see* PURKISS A.G.
O'SHEA D., KIM R.B. & WILKINSON R.B. Modulation of CYP2E1 activity by isoniazid in fast and slow N-acetylators, 438P
O'SHEA N. *see* ROBERTS J.
OLIVE G. *see* VAUZELLE-KERVROEDAN F.
OLKKOLA K.T. *see* VARHE A.
ON N. *see* SEABER E.
OTTON S.V., BALL S.E., CHEUNG S.W., INABA T., RUDOLPH R.L. & SELLERS E.M. Venlafaxine oxidation *in vitro* is catalysed by CYP2D6 149

PAECH M. *see* WOJNAR-HORTON R.E.
PAINTAUD G. *see* BENDRISS E.K.
PALMA-AGUIRRE J.A. *see* CASTENADA-HERNANDEZ G.
PARIENTE-KHAYAT A. *see* VAUZELLE-KERVROEDAN F.
PARK B.K. *see* ALLOTT R.L.
PARK B.K. *see* MADDEN S.
PARK B.K. *see* TOMLINSON E.S.
PARK B.K., KITTERINGHAM N.R., PIRMOHAMED M. & TUCKER G.T. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications, 477
PASCAL J-P. *see* COMBIS J-M.
PASCHER W. *see* MICHEL M.C.
PATAT A. *see* MATTILA M.J.
PATAT A., TROCHERIE S., ROCHAT C., POTIN C., ALLAIN H. & GANDON J.M. Effect of piribedil on EEG, psychomotor and cognitive function in healthy young subjects, 455P
PATEL J.K.M., McMILLAN A-M., REVELEY M.A. & DURSUN S.M. A clinical and quality of life comparison of sulpiride and chlorpromazine in schizophrenia, 454P
PAWULA M. *see* BARRETT D.A.
PAYEN J-L. *see* COMBIS J-M.
PAYNE S. *see* INMAN W.H.W.
PEACEY S.R. *see* ROSTAMI-HODJEGAN A.
PEARCE G.L. *see* WILTON L.V.
PEARSON A.D.J. *see* YULE S.M.
PERUCCA E. *see* GIACCONE M.
PETERSON D. *see* PURKISS A.G.
PETIT DE LA RHODIERE G. *see* LEMOZIT J.P.
PFAFFENDORF M. *see* BAAN J.
PHILIPP TH. *see* SCHAFERS R.F.
PHILLIPS A.C. *see* GROSS A.S.
PHILLIPS S. *see* SEABER E.
PIETERS M.S.M. *see* STEVENINCK A.L.
PIGUET V. *see* DESMEULES
PILOWSLY L.S., BUSATTO G.F., TAYLOR M., COSTA D.C., SHARMA D.C., SIGMUNDSSON T., ELL P.J., NOHRIA V. & KERWIN R.W. Striatal dopamine D_2 receptor binding estimated *in vivo* in olanzapine-treated schizophrenic patients by [^{123}I-]-IBZM single photon emission, 439
PIRMOHAMED M. *see* ALLOTT R.L.
PIRMOHAMED M. *see* MADDEN S.
PIRMOHAMED M. *see* PARK B.K.
PISANI F. *see* GIACCONE M.
PONS G. *see* VAUZELLE-KERVROEDAN F.
POSNER J. *see* HUSSEIN Z.
POSNER J. *see* SEABER E.
POTIN C. *see* PATAT A.
POWELL J.R. *see* BYE A.
PRADA C. *see* DEL RIO M.C.
PRICE J.S. *see* FORD G.A.

PRICE L. *see* YULE S.M.
PUKRITTAYAKAMEE S. *see* KRISHNA S.
PURKISS A.G. *see* KIROLLOS C.
PURKISS A.G., CHARLETT A., WRIGHT D.J., CHING D., PETERSON D., O'NEILL C.J.A., WELLER C., DOBBS S.M. & DOBBS R.J. Associations of immunoglobulins IgG, IgA and IgM with treatment in those with diagnosed parkinsonism, and with parkinsonism-like postural abnormality in those without 457P
PUSSARD E. *see* BARENNES H.

RABIN H.R. *see* BRAGER N.P.D.
RAMDANI A. *see* SOBHANI I.
RAVINET L. *see* BARENNES H.
RAWLINS M.D. *see* INMAN W.H.W.
RAYMOND K. & LI R.C. iThink, a tool for business that also teaches pharmacokinetics, 474P
REINHARD H.A. *see* SOMOGYI A.A.
REISCH H. *see* BRAGER N.P.D.
RENWICK A.G. *see* ROBERTS J.
REPP H. *see* BLECK J.S.
REVELEY M.A. *see* PATEL J.K.M.
REY E. *see* VAUZELLE-KERVROEDAN F.
RIDDELL J.G. *see* TAYLOR K.
RIEUTORD A. *see* GROSS A.S.
RILEY R.J., SLEE D., MARTIN C.A., WEBBORN P.J.H., WATTAM D.G., JONES T. & LOGAN C.J. *In vitro* evaluation of pharmacokinetic interactions between remacemide hydrochloride and established anticonvulsants, 461P
RING B.J., BINKLEY S.N., VANDENBRANDEN M. & WRIGHTON S.A. *In vitro* interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CY3A 181
ROBERTS J., WALLER D.G., RENWICK A.G., O'SHEA N., MACKLIN B.S. & BULLING M. The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers, 331
ROBIN D.W. *see* KINIRONS M.T.
ROCHAT C. *see* PATAT A.
ROGERS K. *see* JENNINGS M.
ROLAN P. *see* SEABER E.
ROLAN P.E., BENJAMIN P.E., BROOKMAN L., SIOUFI A. & MULLINS F. A model for quantitative estimation of biliary drug excretion in man, 460P
ROMER RASSING M. *see* HERRSTEDT J.
RONCARI G. *see* STEVENINCK A.L.
ROSENZWEIG P. *see* MATTILA M.J.
ROSTAMI-HODJEGAN A., PEACEY S.R., GEORGE E., HELLER S.R. & TUCKER G.T. The insulinergic effect of tolbutamide during euglycaemic clamp in non-diabetic subjects: pharmacokinetic-pharmacodynamic modelling, 464P
RUDAZ S. *see* BONNARBY P; RUDOLPH R.L. *see* OTTON S.V.
RUPRAH M. *see* KRISHNA S.
RUTTER N. *see* BARRETT D.A.

SABBAGH L.C. *see* SOBHANI I.
SALETU B., GRUNBERGER J., ANDERER P., LINZMAYER L. & KONIG P. On the cerebro-protective effects of caroverine, a calcium channel blocker and antiglutaminergic drug: double-blind, placebo-controlled, EEG mapping and psychometric studies under hypoxia, 89
SCHAFERS R.F., MUNCK A.C., WITZE O., DAUL A.E., MICHEL M.C. & PHILIPP TH. Construction of cumulative dose-reponse curves for dopamine and angiotensin II induced changes in renal haemodynamics in healthy volunteers, 441P
SCHALL R. *see* MULLER F.O.
SCHIFF M. *see* BULLINGHAM R.
SCHMID O. *see* THURAUF N.
SCHMIDER J., GREENBLATT D.G., VAN MOTKE L.L., HARMATZ J.S., SHADER R.I., MASIMAMASIMIREMBWA C.M., GUSTAFSSON L.L., DAHL L-L., ABDI Y.A. & HASLER J.A. Inhibition of cytochrome P450 by nefazodone *in vitro*: studies of dextromethorphan *O*- and *N*-demethylation, 339
SCHMIDER J., GREENBLATT D.J., HARMATZ J.S. & SHADER R.I. Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline *N*-demethylation, 593
SCHMIDT D. *see* CHRISTIANS U.
SCHOEMAKER R.C. *see* STEVENINCK A.L.
SCHOTTMANN R. *see* CHRISTIANS U.
SCHROR K. *see* KLOCKENBUSCH W.
SCHUMANN F. *see* MULLER F.O.
SCIBERRAS D.G. *see* NEWBY D.E.
SEABER E., ON N., PHILLIPS S., CHURCHUS R., POSNER J. & ROLAN P. The tolerability and pharmacokinetics of the novel antimigraine compund 311C90 in healthy male volunteers, 141
SEJERSTED O.M. *see* GULLESTAD L.
SELLERS E.M. *see* OTTON S.V.
SEPPALA T. *see* MATTILA M.J.
SETO W-H., CHING T-Y., KOU M., CHIANG S-C., LAUDER I.J. & KUMANA C.R. Hospital antibiotic subscribing successfully modified by 'immediate concurrent feedback' 229
SEWING K.F. *see* BLECK J.S.
SEWING K-F. *see* CHRISTIANS U.
SEYMOUR R.A. *see* MOORE V.R.
SEYMOUR R.A., KELLY P.J. & HAWKESFORD J.E. The efficacy of ketoprofen and paracetamol (acetominophen) in postoperative pain after third molar surgery, 581
SHADER R.I. *see* SCHMIDER J.
SHAM J.S.T. *see* CHUA D.T.T.
SHARMA D.C. *see* PILOWSLY L.S.
SHARMA S.C. & FEELY J. The influence of aspirin and paracetamol on blood concentrations of alcohol in young adults, 467P
SHAW P.N. *see* BARRETT D.A.
SHAY S. *see* KINIRONS M.T.
SHEEHAN R. *see* CHAN R.
SHENFIELD G.M. *see* GROSS A.S.
SHYU W.C., MORGENTHEIN E.A. & BARBHAIYA R.H. Pharmacokinetics of butorphanol nasal spray in patients with renal impairment, 387
SIEGMUND W. *see* HADASOVA E.
SIEPMANN M. *see* EBERT U.
SIGMUNDSSON T. *see* PILOWSLY L.S.
SILKE B. *see* TAYLOR K.
SIOUFI A. *see* ROLAN P.E.
SIPS A.J.A.M., BARTO R., VAN DER VIJGH W.J.F. & NETELENBOS J.C. Intestinal absorption of strontium chloride in healthy volunteers: pharmacokinetics and reproducibility, 543
SKAGEN K. *see* KELBAEK H.
SLEE D. *see* RILEY R.J.
SMITH C.A.D. *see* JENNINGS M.
SMITH J. *see* CHAN R.
SMITH R.A. *see* SRINIVAS N.R.
SOBHANI I., RAMDANI A., BAYOD F., SABBAGH L.C., THOMAS F. & MIGNON M. Lanreotide inhibits human jejunal secretion induced by prostaglandin E_1 in healthy volunteers, 109
SODHI M.S., ARRANZ M.J., BALL D.M., AITCHISON K.J., ABUSAAD I., KERWIN R.W. & COLLIER D.A. Association between psychoses and allelic variation in 5-HT_{2A} and 5-HT_{2c} receptor genes, 457P
SOEDIRMAN J.R., DE BRUIJN E.A., MAES R.A.A., HANCK A. & GRUTER J. Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (Vitamin K1) mixed micelles formulation, 517
SOMOGYI A.A., REINHARD H.A. & BOCHNER F. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism, 175
SOMVILLE T. *see* KLOCKENBUSCH W.
SOONS P.A. *see* KAMALI F.
SPITZER W.O. Rebuilding confidence in oral contraceptives: a new imperative in family planning, 359
SPITZER W.O., HEINEMANN L., LEWIS M. & THOROGOOD M. Do third generation low-dose oral contraceptives increase the occurrence of venous thromboembolism, 445P
SRINIVAS N.R., KNUPP C.A., BATTEIGER B., SMITH R.A. & BARBHAIYA R.H. A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients, 207
STARR A. *see* HE G-W.

STEER P.A. *see* LEE T.C.
STEPNIEWSKA K. Book review. Analysing survival data from clinical trials and observational studies by E. Marubini & M.G. Valsecchi, 76
STEVENINCK A.L., GIESCHKE R., SCHOEMAKER R.C., RONCARI G., TUK B., PIETERS M.S.M., BREIMER D.D. & COHEN A.F. Pharmacokinetic and pharmacodynamic interactions of bretazenil and diazepam with alcohol, 565
SUPANARANOND W. *see* KRISHNA S.
SUTTON J.A., MOULD G.P., KILMINSTER S.G., CAPONE P. & DEL RE G. The hypotensive effects of five repeated daily doses of a novel angiotensin II inhibitor, LRB-081, in normotensive volunteers, 448P
SWANSON J. *see* HE G-W.
SWEETLAND H. *see* JENNINGS M.
SZABADI E. *see* ABDELMAWLA A.H.
SZABADI E. *see* BITSIOS P.
SZABADI E. *see* MORTLOCK S-A.

TAN C.C. *see* LEE H.S.
TAN K.S. *see* CLARK D.J.
TAN K.S., McFARLANE L.C., COUTIE W.J. & LIPWORTH B.J. Effects of exogenous female sex-steroid hormones on lymphocyte β_2-adrenoceptors in normal females, 414
TAN K.S., McFARLANE L.C., COUTIE W.J. & LIPWORTH B.J. Effects of exogenous female sex-steroid hormones on lymphocyte β_2-adrenoceptors in normal females, 458P
TANNER J. *see* LEENEN F.H.H.
TASSO M.J. *see* YULE S.M.
TAYLOR K., SILKE B. & RIDDELL J.G. Development of time-domain measures of heart rate variability to overcome both data on-stationarity and need to interpolate missing data points, 446P
TAYLOR K., SILKE B. & RIDDELL J.G. Effect of propranolol on heart-rate variability in normal volunteers using standard time-domain statistics and a new non-linear parameter, 447P
TAYLOR M. *see* PILOWSLY L.S.
TEICHMANN W. *see* WEISS M.
TETT S., DAY R. & CUTLER D. Hydroxychloroquine relative bioavailability:within subject reproducibility, 244
TETT S.E. *see* McLACHLAN A.J.
THIEN T. *see* VEERMAN D.P.
THIESEMANN C. *see* BLECK J.S.
THOMAS F. *see* SOBHANI I.
THOMAS M., MACONOCHIE J.G. & FLETCHER E. The dilemma of the prolonged QT interval in early drug studies, 77
THOMAS S.H.L. & HARTIGAN-GO K. Stereoselective effect of terodiline on ventricular repolarisation in healthy subjects, 442P
THOMAS S.H.L. *see* HARTIGAN-GO K.
THOMAS S.H.L. *see* HUSSAIN R.M.
THOMAS S.H.L. *see* MASOOD A.R.
THOROGOOD M. *see* SPITZER W.O.
THURAUF N., FLEISCHER W.K., LIEFHOLD J., SCHMID O. & KOBAL G. Dose dependent time course of the analgesic effect of a sustained-release preparation of tramadol on experimental phasic and tonic pain, 115
TI T.Y. *see* LEE H.S.
TOMLINSON E.S., MAGGS J.L., PARK B.K. & BACK D.J. Dexamethasone metabolism *in vitro*: species differences in 6-hydroxylation, 462P
TOMMEY R. *see* KAMALI F.
TOPMILLER M.J. *see* WALLE T.
TRELOAR A.J., ASSIN M. & MACDONALD A.J.D. Pupillary response to topical tropicamide as a marker for Alzheimer's disease, 256
TROCHERIE S. *see* PATAT A.
TRUTWEIN D. *see* JIA H.
TUCKER G.T. *see* COLEMAN T.
TUCKER G.T. *see* JENNINGS M.
TUCKER G.T. *see* PARK B.K.
TUCKER G.T. *see* ROSTAMI-HODJEGAN A.
TUK B. *see* STEVENINCK A.L.
TURCK D. *see* NARJES N.

UNGERER M.J. *see* MULLER F.O.

VAN DER VIJGH W.J.F. *see* SIPS A.J.A.M.
VAN MONTFRANS G.A. *see* VEERMAN D.P.
VAN MOTKE L.L. *see* SCHMIDER J.
VAN ZWEITEN P.A. *see* BAAN J.
VANDENBRANDEN M. *see* RING B.J.
VARHE A., OLKKOLA K.T. & NEUVONEN P.J. Fluconazole but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism, 319
VAUZELLE-KERVROEDAN F., REY E., CIEUTA C., PARIENTE-KHAYAT A., PONS G., D'ATHIS P., BIDAULT R., DULAC O. & OLIVE G. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamogritine as add-on therpay in epileptic children, 325
VEAL G.J. *see* HOGGARD P.G.
VEAL G.J., BARRY M.G., KHOO S. & BACK D.J. Intracellular phosphorylation of zidovudine in patients receiving two different dosage regimens, 473P
VEERMAN D.P., DOUMA C.E., JACOBS M-C., THIEN T. & VAN MONTFRANS G.A. Effects of acute and chronic angiotensin converting enzyme inhibition by spirapril on cardiovascular regulation in essential hypertensive patients. Assessment by spectral analysis and haemodynamic measurements, 49
VENTRESCA G.P. *see* FALCOZ C.
VENTRESCA G.P. *see* MACKIE A.E.
VERDIER R. *see* BARENNES H.
VERMEIJ P. *see* BAAN J.
VEUTHEY J-L. *see* BONNARBY P; VINEL J-P. *see* COMBIS J-M.
WAINER I.W. *see* DUCHARME J.
WALLACE R.J. *see* KAMALI F.
WALLE T. *see* EATON E.A.
WALLE T., FAGAN T.C., WALLE U.K. & TOPMILLER M.J. Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women, 305
WALLE U.K. *see* EATON E.A.
WALLE U.K. *see* WALLE T.
WALLER D.G. *see* ROBERTS J.
WATKINS W.M., MUNGAI M., MUHIA D.K., MBERU E.K., GATHUA S., WINSTANLEY P.A., GILKS C.F. & NUNN P. Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma, 160
WATTAM D.G. *see* RILEY R.J.
WEBB D.J. *see* FERRO C.J.
WEBB D.J. *see* HAYNES W.G.
WEBB D.J. *see* NEWBY D.E.
WEBB E., ASHTON C.H., KELLY P. & KAMALI F. Lifestyles, alcohol and drug abuse in medical students, 445P
WEBBORN P.J.H. *see* RILEY R.J.
WEISS M., HUBNER G.H., HUBNER I.G. & TEICHMANN W. Effects of cardiac output on disposition kinetics of sorbitol: recirculatory modelling, 261
WELLER C. *see* KIROLLOS C.
WELLER C. *see* PURKISS A.G.
WEN Y. & FEELY J. Effect of pharmacologic supplementation of vitamin C on lipid peroxidation, 472P
WESNES K. *see* EBERT U.
WESTGATE C. *see* CHAN R.
WESTHOFF-BLECK M. *see* BLECK J.S.
WHITE N.J. *see* KRISHNA S.
WILHELM M. *see* KLOCKENBUSCH W.
WILKINSON R.B. *see* O'SHEA D.
WILLIAMS B.C. *see* BURNS N.
WILLIAMS P.M. & HOUSOM L. The readability of volunteer consent forms: a comparison of pharmaceutical companies and contract research organisation, 466P
WILSON H.M. *see* EATON E.A.
WILTON L.V., PEARCE G.L. & MANN R.D. A comparison of ciprofloxacin, azithromycin and cefixime examined by observational cohort studies, 277
WINSTANLEY P.A. *see* WATKINS W.M.
WITZE O. *see* SCHAFERS R.F.
WALKER J.S. & DAY R.O. Experimental pain techniques, 349
WOJNAR-HORTON R.E., HACKETT L.P., YAPP P., DUSCI L.J., PAECH M. & ILETT K.F. Distribution and excretion of sumatriptan in human milk, 217
WOLF C.R. *see* JENNINGS M.
WONG H. *see* GRAHAM S.
WOOD A.J.J. *see* KINIRONS M.T.
WOOD J. *see* HE G-W.
WOOD S.M. *see* FORD G.A.
WOOD S.M. *see* INMAN W.H.W.
WOODING S.J. *see* KAMALI F.
WOODS H.E. *see* JENNINGS M.

WRIGHT D.J. *see* PURKISS A.G.
WRIGHT R.A. *see* BURNS N.
WRIGHTON S.A. *see* RING B.J.
WYLLIE R. *see* YULE S.M.

YANG C-Q. *see* HE G-W.
YAPP P. *see* WOJNAR-HORTON R.E.
YAU C.C. *see* CHUA D.T.T.
YOGENDRAN L. *see* FALCOZ C.
YULE S.M., BODDY A.V., COLE M., PRICE L., WYLLIE R., TASSO M.J., PEARSON A.D.J. & IDLE J.R. Cyclophosphamide pharmacokinetics in children, 13

ZELENKOVA O. *see* HADASOVA E.
ZIELENIUK I. *see* MATTILA M.J.
ZIPPI P. *see* DEL BIANCO E.
ZSCHIESCHE M. *see* HADASOVA E.

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings)

α_2-adrenoceptor antagonist, 7
A priori estimates of correlation, 235
ACE inhibition, 49
AIDS, 291
Absorption, 250
Acenocoumarol, 525
Acetylcholine, 444P
Acidic media, 1
Activated rigidity, 557
Adenylyl cyclase, 465P
Adjunctive malaria, 29
Adverse drug reaction reporting, 434, 471P
Adverse drug reaction reporting—a reply, 435
Adverse drug reaction reports, 468P
Adverse drug reactions, 166
Adverse effects, 473P
Ageing, 73, 557
Akaike's Information Criterion, 593
Albuterol, 35, 201
Alcohol, 445P, 467P
Alcohol drug-interaction, 253
Alcohol interaction, 565
All-*trans* retinoic acid, 609
Allopurinol, 299
Alniditan, 456P
Alzheimer's disease, 256
Amine neurotransmission, 355
Amisulpride, 454P
Amitriptyline, 593
Analgesics, 7
Angiotensin II, 447P, 449P, 441P
Angiotensin II inhibitor, 448P
Anti-anxiety drugs, 355
Anti-asthma drugs, 285
Anti-bacterial agents, 125
Anticoagulants, 525
Anticonvulsants, 461P
Antidepressants, 355
Antidepressive agents, 21
Anti-diarrhoeal agents, 125
Antiemesis, 403
Antiemetics, 613
Antiepileptic drugs, 325
Antifungal, 291
Antiglutamatergic drug, 89
Antipsychotics, 356
Anxiety, 356
Apnoea, 191
Aprotinin, 619
Artemisinin, 587
Aspirin, 369, 467P
Assay methodology, 425
Asthma bronchiale, 285
Atrial fibrillation, 369
Atropine, 452P
Attention variability, 89
Autonomic nervous system, 49
Azithromycin, 277

β-adrenoceptor antagonist, 443P
β-adrenoceptor blockers, 409
β_2-adrenoceptors, 414

BEAS-2B cells, 201
Benzhexol, 331
Benzodiazepine receptor inverse agonists, 259
Bezafibrate, 381
Biliary excretion, 460P
Bioavailability, 191, 244, 250, 417, 459P, 613
Bipolar affective disorder, 157
Bisoprolol, 443P
Blood pressure variability, 49
Book review, 76, 259, 351
Brain protection, 89
Breast cancer, 461P
Breast milk, 217
Bretazenil, 565

CYP1A2, 421, 438P
CYP1A2 activity, 605
CYP2C19, 181, 461P
CYP2C9, 181
CYP2D6, 149, 181, 339, 438P, 461P
CYP2E1, 438P
CYP3A, 181
CYP3A3/4, 339
CYP3A4, 438P
Caffeine, 169, 421, 605
Calcium antagonists, 83
Calcium channel blocker, 89
Capsaicin, 1
Captopril, 452P
Carbamazepine, 463P, 464P, 575
Cardiac failure, 452P
Cardiotoxicity, 462P
Caroverine, 89
Cefixime, 277
Children, 325, 389
Chinese, 403
Chlorofluorocarbon, 247
Chloroquine, 344
Chlorpromazine, 454P
Ciprofloxin, 277
Circulatory model, 261
Cirrhosis, 409
Cisplatin, 403
Clearance, 477
Clinical pharmacology, 365
Clinical research, 467P
Clinical trials, 76
Clonidine, 269
Clozapine, 181
Cluster headache, 269
Co-amoxiclav, 229
Cognitive function, 455P
Compliance, 83
Congestion pressures, 449P
Congestive heart failure, 452P
Consent forms, 466P
Correlation between treatment modalities, 235
Cost-effectiveness, 229
Cotrimoxazole, 125
Crossover design, 235

Cycloguanil, 175
Cyclooxygenase, 241
Cyclooxygenase inhibition, 450P
Cyclophosphamide, 13
Cyclosporine, 551
Cystic fibrosis, 157
Cytochrome, 477
Cytochrome P450, 69, 181, 311, 339, 525, 593, 609
Cytochrome P450 3A, 187
Cytochrome P4502D6, 428

Debrisoquine, 311
Debrisoquine hydroxylase, 344
13-*O*-demethyl tacrolimus, 187
Depression, 356
Dexamethasone, 403, 462P
Dexfenfluramine, 311
Dextromethorphan, 339
Diabetes, 443P, 450P
Diagnosis, 256
Diamorphine, 531
Diazepam, 565
Dichloroacetate infusion, 29
Didanosine, 207
Dihydropyrimidine, 425
Diltiazem, 551
Distribution clearance, 261
Doctors, 469P
Dopamine, 441P
Dopamine D_2 receptor, 439P
Doppler echocardiography, 447P
Dorsal hand vein, 449P, 450P
Dose regimen, 531
Drug absortion, 331
Drug abuse, 445P
Drug interaction, 13, 525, 551, 575
Drug interactions, 181, 187
Drug metabolism, 477
Drug prices, 470P
Drug reaction, 160
Drug regulation, 351
Drug-utilization trends, 253
Drugs, 166
Dry powder inhaler, 247
Duration of action, 83

EEG, 455P
EEG mapping, 89
Early drug studies, 77
Efficacy, 389, 587
Electroencephalogram, 115
Enantiomers, 35
Enantioselective metabolism, 35
Enantioselectivity, 201, 347
End-stage renal failure, 41
Enemas, 613
Enzyme, 593
Enzyme induction, 477, 575
Epilepsy, 325
Ethanol, 129, 454P
Ethinyloestradiol, 305
Ethnic, 69, 433

© 1996 Blackwell Science Ltd

Ethosuximide, 575
Event-related potential, 115
Exercise, 381
Extracellular volume, 261
Eye, 256

Falciparum malaria, 389
Family planning, 359
Fat oxidation, 381
Female sex steroid hormones, 458P
Fine motor activity, 89
Flucloxacillin-methotrexate interaction, 223
Fluconazole, 291, 319
Fluticasone propionate, 459P, 539
Fluvastatin, 381
Food antacid, 513
Forearm blood flow, 241
Frusemide, 450P

GABAergic synaptic transmission, 355
Gastric emptying, 331
Gender, 605
Generic prescribing, 470P
Genetic polymorphism, 311
Glucocorticosteroid, 539
Glucuronidation, 477
Glutathione S-transferase, 463P
Glyceryl trinitrate, 443P
GsA phenotype, 465P

HIV, 207
HIV infection, 160
Haemodialysis and chronic ambulatory peritoneal dialysis, 41
Healthy subjects, 77, 539
Heart rate, 57
Heart rate variability, 447P
Hepatic plasma flow, 261
Hospital doctors, 472P
Hospital medicine, 166
5-HT_1 receptor agonist, 141
5-HT_{2A} receptor agonist, 457P
5-HT_{2C} receptor agonist, 457P
Human, 477
Human jejunal secretion, 109
Human kinetics, 129
Human liver microsomes, 149, 339
Human microsomes, 187
Human volunteers, 417
Humans, 181
Hydroxychloroquine, 244, 347
6-hydroxylation, 462P
Hypertension, 49, 83
Hypertonicity, 1
Hypoxia, 89
Hypoxic hypoxidosis, 89

Immediate concurrent feedback, 229
Immunoglobulins, 457P
In vitro oxidation, 149
Indomethacin, 241
Inhaled corticosteroids, 285
Inhibition, 241, 421
Interaction, 129, 207, 319, 513
Intestinal absorption, 543
Intra-individual variation, 543
Intracellular phosphorylation, 473P, 474P
Intramuscular, 517
Intrarectal, 389
Intrarectal quinine cream, 389
Intravenous, 517, 539
Intravenous infusion, 531
Isoniazid, 438P
Isosorbide dinitrate, 493
iThink, 474P

Ketoprofen, 581

LRB-081, 448P
Lactation, 217
Lactic acidosis malaria, 29
Lamotrigine, 325
Laser Doppler flowmetry, 1
Levodopa, 331
Lifestyle, 445P
Limited list, 471P
Lipid peroxidation, 472P
Lithium, 157
Liver, 477
Loperamide, 125
Loperamide oxide, 125
Losartan, 449P
Low molecular weight heparin, 163
Lung bioavailability, 247
Lung bronchial epithelial cells, 201
Lymphocyte, 414
Lymphocyte β_2-adrenoceptors, 458P
Lymphocytes, 465P

MPTP, 438P
MST Continus, 417
Major depression, 428
Mammary artery, 101
Maximal work, 57
Medical students, 445P
Medications, 469P
Medicines, 471P, 557
Meeting report, 354
Mefloquine, 587
Meloxicam, 135
Memory, 89, 454P
Menstrual cycle, 414
Metabolic polymorphism, 428
Metabolic probe, 169
Metabolism, 187, 305, 421, 551
Metered dose inhaler, 247
Metered dose inhalers, 459P
Methotrexate, 223
Methoxamine, 269
5-methoxypsoralen, 421
Metoclopramide, 403
Metopimazine, 613
Mexican, 433
Michaelis Menten equation, 593
Migraine, 141, 456P
Milk:plasma ratio, 217
Milrinone, 101
Missing data points, 446P
Mitral regurgitation, 493
Modified release morphine, 417
Morphine, 250, 465P, 531
Morphine-3-glucoronide, 531
Morphine-6-glucoronide, 531
Motivation, 467P
Mycophenolate mofetil, 513

N-acetylators, 438P
N-acetyltransferase, 428
N-acetyltransferase type 2, 169
NONMEM, 191, 223
NSAIDs, 525
Nadroparin, 163
Nebulizer, 250
Nefazodone, 21, 339
Negative correlations, 235
Neuropeptide Y receptor gene, 476P
Neutral endopeptidase, 440P
Nifedipine, 433, 493
Nitric oxide, 441P, 444P
Nitroglycerin, 101
Nonlinear regression, 592
Norfloxacin, 277
Nucleoside analogues, 474P
Nurses, 469P

Objective measurement, 557
Observational cohort studies, 277
Oestrogen, 414
Ofloxacin, 277
Olanzapine, 181, 439P
Opioids, 7, 115
Oral contraceptives, 305, 359
Oramorph SR, 417
Orthostasis, 49
Oxidation polymorphisms, 461P
Oxybutynin, 73
Oxygen uptake, 57
Oxypurinol, 299

P450, 477
Pain, 1, 349
Pain—a reply, 350
Pain measurement, 7, 115
Pain threshold, 7
Paracetamol, 467P, 581
Paracetamol sulphate and glucuronide, 41
Parallel groups design, 235
Parkinson's disease, 438P
Parkinsonism, 457P, 557
Partial clearance, 175
Paul Turner Memorial Symposium, 353
Performance, 454P, 565
Pharmacists, 469P
Pharmacodynamic modelling, 464P
Pharmacodynamics, 299, 319, 477
Pharmacoepidemiology, 285
Pharmacogenetics, 425, 428
Pharmacokinetic modelling, 464P
Pharmacokinetics, 13, 21, 35, 69, 135, 141, 160, 175, 191, 207, 217, 223, 261, 319, 325, 331, 389, 417, 440P, 453P, 461P, 474P, 477, 505, 513, 517, 531, 539, 543, 551, 565, 587, 619
Pharmacovigilance, 166, 277
Phenobarbitone, 575
Phenolsulphotransferase, 201
Phenotyping, 175, 344
Phosphodiesterase, 101
Phylloquinone (vitamin K_1), 517
Piribedil, 455P
Piroxicam, 525
Placebo, 473P
Plasmodium falciparum malaria, 29, 587
Platelets, 163, 616
Polymorphism, 43P, 463P
Population, 191
Population pharmacokinetics, 291
Portal hypertension, 409
Postoperative pain, 581
Prazosin, 451P
Pre-eclampsia, 616
Pregnancy-induced hypertension, 616

Premature infants, 191
Premature newborn, 531
Prescribing, 471P
Prescription event monitoring, 277
Private medicine, 166
Progesterone, 414
Proguanil, 175
Propranolol, 57, 305, 447P
Prostacyclin receptor, 616
Psychiatry, 157
Psychological performance, 453P
Psychometry, 89
Psychoses, 457P
Pulmonary artery pressure, 447P
Pupil, 269
Pupillary light reflex, 451P

QT dispersion, 448P
QT interval, 73, 499, 448P
QT interval prolongation, 77
Quality of life, 454P

RIII reflex, 7
Radionuclide cardiography, 493
Ranitidine, 129
Remacemide hydrochloride, 461P
Renal allograft recipients, 551
Renal clearance, 157
Renal haemodynamics, 441P
Renal impairment, 619
Repolarization, 499
Retinoids, 609
Reverse-rate dependence, 499
Rheumatoid arthritis, 223

S-mephenytoin hydroxylase, 344
Salbutamol, 35, 201, 247, 440P, 459P
Saliva and plasma paracetamol correlation, 41
Schizophrenia, 356, 428, 439P, 454P
Scopolamine, 453P
Serotonin, 241
78C90, 505
Single photon emission tomography, 439P
619C89, 505
Skin, 1
Smoking, 605
Sodium nitroprusside, 443P
Somatostatin, 109
Sorbitol, 261
Southern Asians, 69
Sparfloxacin, 499
Statistical assessment, 235
Statistical power, 235
Steady-state, 21
Stereoselectivity, 201, 442P
Stroke, 369, 505
Strontium, 543
Subjective perception of fatigue, 57
Substance P, 444P, 445P
Sulphamethoxazole, 207
Sulphation, 201
Sulpiride, 454P
Sultamicillin, 229
Sumatriptan, 217, 456P

Tacrolimus, 187
Terbinafine, 319
Terodiline, 442P, 462P
Theophylline, 191
Thiacetazone, 160
Third molar surgery, 531
311C90, 141
341C90, 505
Thrombin, 163
Thromboembolism, 369, 359
Time-domain measures, 446P
Time-domain statistics, 447P
Tolbutamide, 464P
Tolerability, 135, 141
Tolerance, 517
Toxicity, 477, 605
Training, 365
Tramadol, 7, 115
Triazolam, 69, 319
Trimethoprim, 207
Tropicamide, 256
Tropisetron, 403
Tyramine, 269

Urate, 299

Variation, 13
Vascular tone, 440P
Vasoconstriction, 443P
Vasodilators, 409
Venlafaxine, 149
Vitamin C, 472P
Volunteers, 467P, 473P

Warfarin, 369
Watery diarrhoea, 109
Women, 305

Xanthine oxidase, 299

Yellow card system, 462P
Yohimbine, 7

Zidovudine, 47P